The World Health Organization identifies lung cancer as the leading cause of cancer-related
mortality and one of the highest-incidence cancer types. Within the 85% of all lung cancer …

Precision oncology has fundamentally changed how we diagnose and treat cancer. In
recent years, there has been a significant change in the management of patients with …

Lung cancer remains the leading cause of malignancy-related mortality worldwide, with over
one million cases diagnosed yearly. Non-small-cell lung cancer (NSCLC) accounts for> …

Simple Summary The discovery of actionable oncogenic driver mutations in non-small-cell
lung cancer (NSCLC) has revolutionized the treatment and prognosis of this dreadful …

Clinical trial data continue to emerge on treatments in advanced non-small cell lung cancer
(NSCLC), supporting the strategy that histology and molecular driver mutations should guide …

In recent years, there has been a major paradigm shift in the management of non-small cell
lung cancer (NSCLC). NSCLC should now be further sub-classified by histology and driver …

The treatment landscape for non-small-cell lung cancer (NSCLC) has dramatically shifted
over the past two decades. Targeted or precision medicine has primarily been responsible …

There have been remarkable advances in the targeted treatment of advanced non-small cell
lung cancer (NSCLC) over the past several years. Survival outcomes are steadily improving …

Abstract Purpose of Review Lung cancer remains the leading cause of cancer-related
mortality worldwide. Genetic and molecular profiling of non-small cell lung cancer (NSCLC) …

Non-small cell lung cancer (NSCLC) accounts for approximately 80–85% of all cases of lung
cancer, and it is the most common cause of death in men and second only to breast cancer …